Literature DB >> 17141580

The validation of a bioanalytical method for the determination of clopidogrel in human plasma.

A Robinson1, J Hillis, C Neal, A C Leary.   

Abstract

A fast, sensitive and specific LC-MS/MS bioanalytical method for the determination of unchanged clopidogrel in human plasma has been developed and validated over the range of 10-12,000 pg mL(-1) (r2 0.9993) by the Contract Research group at HFL. Samples (0.3 mL) were buffered (pH 6.8), extracted using diethyl ether and 10 microL of the sample extract was injected onto the LC-MS/MS system. Analysis was performed using a C8 column (temperature controlled to 50 degrees C) by gradient elution at a flow rate of 0.9 mL min(-1) over a 3 min run time. Retention times of 1.61 and 1.59 min were observed for clopidogrel and 2H3-clopidogrel (I.S.), respectively. Detection was achieved using a Sciex API 4000, triple quadrupole mass spectrometer, in positive TurboIonspray (electrospray) ionisation mode. Ion transitions were monitored using MRM (multiple reaction monitoring) for clopidogrel (m/z 322-212) and for 2H3-clopidogrel (m/z 327-217). This validated method was used to support a pharmacokinetic study in healthy volunteers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141580     DOI: 10.1016/j.jchromb.2006.10.076

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  6 in total

1.  A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma.

Authors:  Cody J Peer; Shawn D Spencer; Dustin A H VanDenBerg; Michael A Pacanowski; Richard B Horenstein; William D Figg
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-11-26       Impact factor: 3.205

2.  A comparison of two brands of clopidogrel in patients with drug-eluting stent implantation.

Authors:  Yae Min Park; Taehoon Ahn; Kyounghoon Lee; Kwen-Chul Shin; Eul Sik Jung; Dong Su Shin; Myeong Gun Kim; Woong Chol Kang; Seung Hwan Han; In Suck Choi; Eak Kyun Shin
Journal:  Korean Circ J       Date:  2012-07-26       Impact factor: 3.243

3.  Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions.

Authors:  Helena Leonie Hanae Loer; Denise Türk; José David Gómez-Mantilla; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-04-22       Impact factor: 6.525

4.  Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma.

Authors:  Gangyi Liu; Chunxia Dong; Weiwei Shen; Xiaopei Lu; Mengqi Zhang; Yuzhou Gui; Qinyi Zhou; Chen Yu
Journal:  Acta Pharm Sin B       Date:  2015-12-15       Impact factor: 11.413

5.  Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention.

Authors:  Urszula Adamiak-Giera; Anna Czerkawska; Szymon Olędzki; Mateusz Kurzawski; Krzysztof Safranow; Maria Jastrzębska; Barbara Gawrońska-Szklarz
Journal:  Pharmacol Rep       Date:  2020-12-03       Impact factor: 3.024

6.  Development and Validation of an HPLC Method for Simultaneous Quantification of Clopidogrel Bisulfate, Its Carboxylic Acid Metabolite, and Atorvastatin in Human Plasma: Application to a Pharmacokinetic Study.

Authors:  Octavian Croitoru; Adela-Maria Spiridon; Ionela Belu; Adina Turcu-Ştiolică; Johny Neamţu
Journal:  J Anal Methods Chem       Date:  2015-12-29       Impact factor: 2.193

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.